Sanofi SA / Origimm Biotechnology GmbH

Acne vulgaris (preventive vaccine)

50M US cases/yr · $10.0B Global acne treatment market 2021 (USD MM, Grand View Research) · 85 % lifetime prevalence among adolescents (%)

Disease Overview

Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit driven by multiple factors: hyperkeratinization of follicles, sebum overproduction, dysbiosis of Cutibacterium acnes (formerly Propionibacterium acnes), and inflammation. It affects approximately 50 million Americans annually and is the most common skin condition in the US (American Academy of Dermatology). Lifetime prevalence approaches 85% in adolescents and persists in 12-22% of adult women. Severe nodulocystic acne can cause permanent scarring and significant psychosocial morbidity, including elevated rates of depression and suicidal ideation. The current treatment paradigm relies on topical retinoids, benzoyl peroxide, antibiotics (oral and topical), hormonal therapy (oral contraceptives, spironolactone), and isotretinoin for severe disease — all symptomatic, none preventive. The global acne treatment market was valued at approximately $10 billion in 2021 (Grand View Research) and is growing at ~5% CAGR. A preventive vaccine targeting acne-pathogenic C. acnes strains would be transformational and first-in-class. ORI-001 is a recombinant protein-based therapeutic vaccine targeting selected C. acnes surface antigens.

Competitive Landscape

No preventive acne vaccine has ever been approved. The acne therapeutic competitive set is dominated by small-molecule and topical incumbents: isotretinoin (generic, plus Absorica/Galderma; ~700K US scripts annually); topical retinoids — tretinoin, adapalene (Differin OTC, Galderma), tazarotene (Arazlo, Bausch); benzoyl peroxide combinations; topical antibiotics — clindamycin, erythromycin; oral antibiotics — doxycycline, minocycline, sarecycline (Seysara, Almirall, FDA approved Oct 2018, first tetracycline specifically for acne); hormonal — combined oral contraceptives, spironolactone; clascoterone (Winlevi, Sun Pharma, FDA approved Aug 2020, first-in-class topical androgen receptor inhibitor); trifarotene (Aklief, Galderma, FDA approved Oct 2019). On the acne vaccine R&D side, prior efforts have been almost entirely academic (UC San Diego Huang Lab, INSERM/Pasteur Institut, French CNRS) without commercial-stage advancement. Sanofi's strategic logic combines Origimm's protein-antigen identification with the mRNA platform inherited from Translate Bio (acquired Aug 2021 for $3.2B) to enable platform reuse and accelerate Phase 1/2 entry. As of 2024, no acne vaccine has entered registrational trials, and Sanofi's mRNA pivot deprioritized non-respiratory programs.